Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.

Slides:

Advertisements

Similar presentations

Advertisements

James R. Rigas Comprehensive Thoracic Oncology Program

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.

Pulmonary Adenocarcinoma Patterns The good, the bad and the ugly C. Black CTOP retreat.

IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Kerrington Smith, M.D. CTOS Nov 14, 2008

S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.

An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Supplemental Table A. Baseline proteinuria predicting renal outcome in multivariable Cox-Hazard model PredictorsHR95% CIp value Baseline UPE, g/day

Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.

Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

until tumour progression until tumour progression

Table S1. CD44 expression and clinicopathologic characteristics Cases (n=54) CD44 protein expression P value* Negativ e WeakStrong (n=8)(n=23) Age

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

Wilms’ tumour gene 1 (WT1) is a new prognostic marker in high grade uterine sarcoma A. Coosemans, B. Van Calster, L. Verbist, Ph. Moerman, I. Vergote,

Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology : R2 Hwang.

1 LUX-Lung 3 clinical trial ECOG=Eastern Cooperative Oncology Group. Sequist LV et al. J Clin Oncol. 2013;31(27): Treatment-naïve Advanced NSCLC.

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.

LUX-Lung 6 clinical trial

LUX-Lung 3 clinical trial

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Fig 1A. Patient enrollment flow chart

Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

Prognosis of younger patients in non-small cell lung cancer

Marcelo Calil Instituto Brasileiro de Controle do Câncer

EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,

Limburg Clinical Research Program

until tumour progression until tumour progression

Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung

Proposed Changes to the 7th Edition

Fig. S1 PIPKI is highly expressed in cancer cell lines

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.

EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.

Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD,

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience Tsuguo Naruke,

Patients who have received chemotherapy (n=60)

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Differences of tumor microenvironment between stage I lepidic-positive and lepidic- negative lung adenocarcinomas Shinya Katsumata, MD, Keiju Aokage,

Disease-specific survival

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma Yasuhiro Tsutani, MD, PhD, Yoshihiro.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese.

Josep M. Llovet, Robert Montal, Augusto Villanueva

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma Tomoharu Yoshiya, MD, Takahiro Mimae, MD, PhD, Yasuhiro.

Supplemental Material

median of follow-up (month)

* OS >3yr with No Next Line * * * * *

Presentation transcript:

Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma Lepidic predominant pT1bN0M0 Negative CAF3 63, FemaleAdenocarcinoma Acinar predominant pT2aN0M0 Negative CAF4 64, MaleAdenocarcinoma Papillary predominant pT2bN1M0 Exon 19 deletion CAF5 55, FemaleAdenocarcinoma Lepidic predominant pT1aN0M0 Exon 19 deletion CAF6 75, MaleAdenocarcinoma Lepidic predominant pT2aN0M0 L858R Supplemental Table 1. Characteristics of primary adenocarcinoma from which CAFs were obtained.

Characteristics Podoplanin expression of CAFs P-value Positive N (%) Negative N (%) Number of patients5749 Predominant Subtype Lepidic predominant Papillary predominant Acinar predominant Solid predominant 4 (7) 25 (44) 6 (11) 22 (39) 10 (21) 29 (59) 5 (10) <0.001* Pathological stage IA / IB IIA / IIB IIIA / IIIB IV 5 (9) / 11 (20) 10 (18) / 1 (2) 26 (44) / 3 (5) 1 (2) 8 (16) / 7 (14) 2 (4) / 1 (2) 23 (48) / 5 (10) 3 (6) 0.326** Lymphatic permeation Positive / Negative 21 (36) / 36 (64) 24 (49) /25 (51) Vascular invasion Positive / Negative 45 (78) / 12 (22) 25(51) / 24 (49) Pleural invasion Positive / Negative 25 (42) / 32 (58) 24 (50) / 25 (50) Pulmonary metastases Positive / Negative 8 (15) / 49 (85) 15 (22) / 34 (78) Supplemental Table 2. Primary tumor characteristics (N=106). * P-value for solid vs non-solid predominant subtype ** P-value for Stage I+II vs III+IV

Variables Univariate analysis P-value Multivariate analysis Hazard ratio95% C. I.P-value PDPN expression (positive) Age (≥70) Gender (male) Performance Status (≥2)< <0.001 Smoking status (smoker) Pathological stage (stage III,IV) EGFR status (Minor mutation) Adjuvant chemotherapy (YES) Vascular invasion (positive) Lymphatic permeation (positive) Pleural invasion (positive) Pulmonary metastases (positive) Supplemental Table 3. Impact of predictive factors on progression free survival of EGFR-TKI in patients with EGFR activating mutation by univariate and multivariate analysis (n=106). PDPN, podoplanin; C. I., confidence interval

Supplemental Table 4. The correlation between PDPN expression status and clinical response to EGFR-TKIs in patients with EGFR common mutations, exon 19 deletion and L858R (N=102). (A) Overall response rate (ORR), (B) Median survival time (MST). EGFR mutation CAF PDPN(-) ORR(%) CAF PDPN(+) ORR(%) P-value L858R (N=56) 78% (N=21) 49% (N=35) Exon 19 deletion (N=46) 86% (N=27) 52% (N=19) EGFR mutation CAF PDPN(-) MST (months) CAF PDPN(+) MST (months) P-value L858R (N=56) Exon 19 deletion (N=46) (A) (B)